ENDRA Life Sciences posts Q2 profit on digital asset gains ahead of merger

ENDRA Life Sciences

17/08/2026 13:09

Overview
US thermoacoustic imaging firm's Q2 net income rose, reversing a loss from prior year
Q2 operating expenses increased, but R&D and sales and marketing costs declined sharply
Company entered definitive merger agreement with Noble Africa; deal expected to close Q4 2026

Outlook
Company expects to complete merger with Noble Africa in Q4 2026, subject to approvals
ENDRA is focused on satisfying conditions necessary to complete the merger transaction

Result Drivers
COST CONTROLS - Co sharply reduced R&D and sales and marketing expenses during strategic alternatives process and pending merger
DIGITAL ASSET GAINS - Net income driven primarily by realized and unrealized gains from digital asset treasury

Company press release: ID:nBw9jBWNHa

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Operating Expenses
 
$1.5 mln
 

Analyst Coverage
The one available analyst rating on the shares is "buy"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for ENDRA Life Sciences Inc is $25.00, about 459.3% above its August 14 closing price of $4.47

Reuters Recommended Reads
Aug 14 - XMax Q2 net income surges driven by unrealized investment gain
Aug 17 - InspireMD Q2 revenue beats estimates on international demand
Aug 14 - Medical device maker Retractable Technologies' Q2 sales drop on weak EasyPoint needle orders

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)